FDA Updates Atripla Labeling
“FDA recently approved updates to the Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate) tablet label to include the following changes:
Lists Stribild as one of the drugs that should not be coadministered with Atripla
Adds drug interaction information for raltegravir, boceprevir and telaprevir
Strengthens Warnings and Precautions: Rash section
Updates the Use in Specific Populations: Nursing Mothers section
Updates Tables 7 and 8 with didanosine drug interaction data based upon recent changes to the prescribing information for Sustiva, Truvada and Viread.”
The updated labeling will be available at the FDA website.
More information is available:
FDA: Press release
AIDSinfo: Atripla patient drug summary
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - Category: Infectious Diseases Source Type: news